STOCK TITAN

Microbot Med Inc - MBOT STOCK NEWS

Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.

Overview

Microbot Medical Inc is a pre-clinical medical device company dedicated to developing next-generation micro-robotic technologies aimed at transforming surgical procedures. The company is at the intersection of advanced robotics and healthcare innovation, focusing on minimally invasive surgery to reduce the trauma associated with traditional surgical access. By integrating state-of-the-art micro-robotic systems with precise automated instruments, Microbot Medical is addressing one of the largest unmet medical needs: minimizing procedural invasiveness while maintaining surgical efficacy.

Technological Innovation

At the core of its operations, Microbot Medical Inc specializes in micro-robotic platforms that enhance surgical precision. Its innovative approach leverages autonomous micro-robot systems, designed to navigate and operate within extremely confined anatomical spaces, thus ensuring a reduction in surgical morbidity. The LIBERTY platform and Self-Cleaning Shunt (SCS) exemplify the integration of robotics and automation, offering advanced solutions across multiple surgical disciplines. With a strong intellectual property portfolio, the company secures its competitive advantage through domestic and global patents.

Industry Context and Market Position

The company operates within the burgeoning field of minimally invasive surgery, a sector characterized by its continuous evolution and robust demand driven by patient and physician preferences for procedures that limit trauma and promote swift recoveries. As healthcare systems increasingly adopt technologies that promise reduced surgical risks and improved precision, Microbot Medical Inc positions itself as a key innovator. The market benefits from the company’s commitment to addressing complex challenges in endovascular robotics and other surgical applications, setting a clear benchmark for precision and disrupting traditional surgical methods.

Operational Approach and Business Model

Microbot Medical Inc generates its potential revenue streams by developing platforms that can be adapted and applied to a range of surgical specialties. The company’s business model is underpinned by extensive R&D, strategic partnerships, and a focus on securing robust patent protection, all of which minimize competitive risks. By targeting procedures where access-induced trauma has historically compromised outcomes, the company has created a niche that leverages technological precision to improve overall surgical safety.

Competitive Advantages and Future Considerations

Within the competitive landscape of medical device innovations, Microbot Medical Inc distinguishes itself through its commitment to blending robotics with minimally invasive techniques. This intersection of fields allows the company to deliver unique value propositions to healthcare providers by reducing the invasiveness inherent in many traditional surgical procedures. The firm’s ongoing focus on research and development, coupled with its strategic intellectual property positioning, underscores its dedication to advancing surgical care without relying on speculative performance projections.

Commitment to Quality and Innovation

Quality, precision, and innovation are the hallmarks of Microbot Medical Inc's approach. The company’s platforms are engineered to assist physicians in targeting disease sites with remarkable precision, significantly lowering the risk of collateral trauma. By consistently pushing the boundaries of micro-robotic applications in surgery, Microbot Medical Inc continues to build a foundation based on expertise and proven technological advancements that support improved surgical outcomes.

Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) successfully completed its GLP pivotal pre-clinical study for the LIBERTY Endovascular Robotic Surgical System. The study results will support the company's IDE submission to the FDA for commencing the human clinical study. Three leading interventional radiologists conducted the study, utilizing the robotic system for 96 navigations, leading to positive histopathology report outcomes. The CEO, Harel Gadot, expressed confidence in the company's transition to the clinical, regulatory, and pre-commercial phase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. (MBOT) appoints Dr. Juan Diaz-Cartelle, former Senior Medical Director at Boston Scientific Corporation, as its new Chief Medical Officer. Dr. Diaz-Cartelle's appointment coincides with the Company's transition to focus on U.S.-based activities, including clinical trials and FDA regulatory processes for the LIBERTY Endovascular Robotic Surgical System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
management
-
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process for its LIBERTY Robotic Surgical System. This achievement is a crucial step towards the company's regulatory submission and the FDA's approval for clinical trials. The V&V process ensures that the product aligns with specified requirements and serves its intended purpose, highlighting Microbot's commitment to quality and safety standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announced the granting of the 'One & Done®' trademark from the US Patent and Trademark Office for its LIBERTY Robotic Surgical System, highlighting its unique feature of integrating guidewires, microcatheters, and other instruments for endovascular procedures. This move expands the company's proprietary assets and sets its product apart in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
none
-
Rhea-AI Summary
Microbot Medical Inc. announces 100% success rate in reaching targets with no adverse events in pre-clinical study using the LIBERTY Robotic Surgical System. The study involved 48 animal targets and visual examination after 72 hours showed no evidence of vascular injury or adverse events. 6 LIBERTY Systems were used, all performing flawlessly with 100% usability and technical success. The company plans to submit an IDE application to the FDA for a pivotal clinical trial in humans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.19%
Tags
-
Rhea-AI Summary
Microbot Medical Inc. has received confirmation for the commencement of the process to support its future CE Mark approval for the LIBERTY® Robotic Surgical System in Europe. The Company will conduct audits for ISO 13485 certification during the first half of 2024 to ensure compliance with EU Medical Devices Regulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Microbot Medical Inc. announces dismissal of counterclaim in legal action
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.53%
Tags
none
-
Rhea-AI Summary
Microbot Medical Inc. announces successful outcomes of pivotal pre-clinical study for LIBERTY Robotic Surgical System
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.96%
Tags
-
Rhea-AI Summary
Microbot Medical partners with a Contract Research Organization (CRO) in the US to support its upcoming clinical trial for the LIBERTY® Robotic Surgical System. The CRO will provide research management services and guidance throughout the trial process, enhancing Microbot's capabilities. This engagement is expected to help the company achieve necessary compliances with the FDA and navigate the regulatory landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
Rhea-AI Summary
Microbot Medical Inc. announces growing global recognition of its LIBERTY® Robotic Surgical System
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
conferences

FAQ

What is the current stock price of Microbot Med (MBOT)?

The current stock price of Microbot Med (MBOT) is $2.05 as of April 22, 2025.

What is the market cap of Microbot Med (MBOT)?

The market cap of Microbot Med (MBOT) is approximately 88.6M.

What is Microbot Medical Inc's primary focus?

Microbot Medical Inc specializes in developing micro-robotic technologies designed for minimally invasive surgical procedures. The company focuses on reducing surgical trauma by using automated instruments for precise disease targeting.

How does the company aim to improve surgical outcomes?

The company leverages advanced micro-robotics to navigate confined anatomical spaces, thereby reducing the trauma associated with traditional surgical access. This precision enhances surgical outcomes and supports improved patient recovery.

What distinguishes Microbot Medical's technology from traditional surgical tools?

Microbot Medical integrates autonomous micro-robotic systems with innovative platforms like LIBERTY and the Self-Cleaning Shunt to augment surgical precision. This approach minimizes invasiveness and lowers the risk of collateral tissue damage compared to conventional methods.

What role does intellectual property play in Microbot Medical's strategy?

The company has secured a portfolio of domestic and global patents, which serve as barriers to entry in a competitive market. This strategic emphasis on patented innovation helps maintain its competitive edge in medical device development.

How does Microbot Medical contribute to the field of minimally invasive surgery?

By developing technologies that enable precise targeting and reduced procedural trauma, Microbot Medical addresses one of the key challenges in surgery. Its focus on micro-robotics provides physicians with new tools to minimize invasiveness and enhance patient safety.

How does Microbot Medical differentiate itself from its competitors?

The company differentiates itself through a strong focus on innovative micro-robotic platforms, robust patent protection, and a commitment to improving surgical precision. Its niche in minimizing access-related trauma sets it apart from traditional surgical device manufacturers.
Microbot Med Inc

Nasdaq:MBOT

MBOT Rankings

MBOT Stock Data

88.60M
34.18M
1.63%
7.48%
14.45%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
HINGHAM